# Immune Globulin Subcutaenous (Human), 20%

> **NCT01412385** · PHASE2,PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 55 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **BIOLOGICAL:** Immune Globulin Subcutaneous (Human), 20%
- **BIOLOGICAL:** Immune Globulin Intravenous (Human), 10%
- **BIOLOGICAL:** Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)

## Key facts

- **NCT ID:** NCT01412385
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-20
- **Primary completion:** 2014-05-13
- **Final completion:** 2014-05-13
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412385, "Immune Globulin Subcutaenous (Human), 20%". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01412385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*